Simulations Plus' (SLP) "Outperform" Rating Reiterated at William Blair

William Blair reissued their outperform rating on shares of Simulations Plus (NASDAQ:SLP - Free Report) in a report released on Tuesday,RTT News reports.

SLP has been the topic of a number of other research reports. Wall Street Zen raised Simulations Plus from a "sell" rating to a "hold" rating in a research report on Monday, April 28th. KeyCorp increased their target price on Simulations Plus from $32.00 to $40.00 and gave the company an "overweight" rating in a report on Wednesday, April 16th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $50.00.

Simulations Plus Price Performance

SLP traded down $0.49 during trading hours on Tuesday, reaching $27.55. The company's stock had a trading volume of 230,241 shares, compared to its average volume of 223,728. Simulations Plus has a fifty-two week low of $23.01 and a fifty-two week high of $50.11. The stock has a market cap of $554.06 million, a PE ratio of 68.88 and a beta of 1.10. The business's 50-day moving average is $30.50 and its 200-day moving average is $30.39.

Simulations Plus (NASDAQ:SLP - Get Free Report) last released its quarterly earnings data on Thursday, April 3rd. The technology company reported $0.31 EPS for the quarter, beating analysts' consensus estimates of $0.25 by $0.06. Simulations Plus had a return on equity of 6.84% and a net margin of 10.97%. The firm had revenue of $22.43 million for the quarter, compared to analysts' expectations of $21.93 million. During the same period in the prior year, the firm posted $0.20 earnings per share. The firm's quarterly revenue was up 22.5% on a year-over-year basis. Analysts expect that Simulations Plus will post 1.09 EPS for the current year.

Insider Buying and Selling at Simulations Plus

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the company's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $33.51, for a total value of $670,200.00. Following the completion of the transaction, the director now owns 3,344,157 shares in the company, valued at $112,062,701.07. This represents a 0.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 19.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Simulations Plus

Several large investors have recently bought and sold shares of SLP. Jones Financial Companies Lllp boosted its stake in shares of Simulations Plus by 53.6% during the fourth quarter. Jones Financial Companies Lllp now owns 1,223 shares of the technology company's stock worth $34,000 after buying an additional 427 shares during the period. Fifth Third Bancorp boosted its stake in shares of Simulations Plus by 33.8% during the first quarter. Fifth Third Bancorp now owns 1,485 shares of the technology company's stock worth $36,000 after buying an additional 375 shares during the period. Johnson Financial Group Inc. acquired a new stake in shares of Simulations Plus during the fourth quarter worth about $39,000. Tower Research Capital LLC TRC boosted its stake in shares of Simulations Plus by 42.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 2,575 shares of the technology company's stock worth $72,000 after buying an additional 764 shares during the period. Finally, AlphaQuest LLC boosted its stake in shares of Simulations Plus by 502.9% during the fourth quarter. AlphaQuest LLC now owns 2,689 shares of the technology company's stock worth $75,000 after buying an additional 2,243 shares during the period. Institutional investors and hedge funds own 78.08% of the company's stock.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.